Home About Clinicians Patients Investors Careers Media Contact Clinicians > About SIR-Spheres microspheres > Radiation Safety Aspects Yttrium-90 has two inherent safety features for staff and patients: the minimal penetration depth of beta radiation emissions through tissue and air the relatively short half-life of 64.1 hours Once patients have received the implant, they effectively become a radiation source. However, patients pose very limited radiation risk to medical staff, family, friends, and the public due to minimal tissue penetration and emissions of the beta radiation. Some general precautions should be observed, as described in the SIR-Spheres Y-90 resin microspheres Package Insert. DOORwaY-90 Study International Recommendations FLEXdose Delivery Programme About SIRT About SIR-Spheres microspheres Mode of Action How are SIR-Spheres microspheres administered Patient Selection Potential adverse events Radiation Safety Aspects Follow Up Peri-Procedural Medications - mCRC Clinical Studies + HCC Clinical Studies + Ongoing Clinical Studies Customer Support and Training Programs Events Frequently Asked Questions Who we are Sirtex Medical is a global healthcare business with offices in the U.S., Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. What are SIR-Spheres® Y-90 resin microspheres? SIR-Spheres® Y-90 resin microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy. To view the Technical Bulletin regarding our indication, click here. Contact or follow us Contact Us SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Terms of Use | Privacy Information 892-EUA-1117